Genentech leaves the numbers blank in Forma deal

Genentech says that it's lined up the worldwide rights to a preclinical cancer program held by Forma Therapeutics in an "innovative" pact, but it's leaving all the numbers blank in its release. Following a research collaboration Genentech can pick up an option on the program, while Forma gets an undisclosed upfront payment along with more undisclosed dollars covering research funding. The biotech also is eligible to receive milestone payments upon the successful achievement of certain development milestones. And if Genentech subsequently acquires the program, Forma "will receive a significant buy-out payment and will be eligible for additional milestone payments if certain sales thresholds are met." Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.